ml -wykrywać i leczyć dzięki zastosowaniu specjalistycznego, odmiennego od standardowego, Systemu badań kontrolnych i postępowania terapeutycznego.

M.

A ..2, 1 3

i

.4.

lit;'

U

PIŚMIENNICTWO

j,” Lynch HT: Genetics and breast cancer. Van Nostrand - Reinhold, New York 1981.

Broca P: Traite de tumeurs. Paris, Asselin 1866.

Miki Y, et al.: A slTong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.

Thompson D, Easton D: Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mula-tion pósition. Cancer Epidemiol Biomarkers Prev 2002; 11: 329-336.

Lichtenstein P, et al.: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from S\\'eden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.

Swift M, et al.: Breast and other cancers in families with ataxiatelangiectasia. N Engl J Med 1987; 316: 1289-1294.

Antoniou AC, et al.: Breast and ovarian cancer risks to carriers of the BRCAI 5382insC and 185delAG and BRCA2 6l74delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005; 42: 602-603.

Gronwald J, et al.: Cancer risks in first degree relatives of BRCAI mutation carriers: effects of mutation and proband disease status. J Med Genet 2006; 43: 424-428.

Risinger JI, et al.: Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994; 1: 98-102.

Thorlacius S, et al.: Populationbased study ofrisk of breast cancer in carriers ofBRCA2 mutation. Lancet 1998; 352: 1337-1339.

Rebbeck TR, et al.: The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCAI or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622. Jakubowska A, et al.: Breast cancer risk reduction associated with the RAD51 polymorphism among carriers ofthe BRCAI 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev 2003; 12: 457-459. Jakubowska A, et al.: The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCAI mutation carriers. Cancer Epidemiol Biomarkers Prev 2007; 16: 270-275.

Risch HA, et al.: Prevalence and penetrance of germline BRCAI and BRCA2 mutations in a population senes of649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-710.    »

Marcus JN, et al.: Hereditary breast cancer: pathobiology, prognosis, and BRCAI and BRCA2 gene linkage, Cancer 1996; 77: 697-709.

Martin AM, et al.: Germline mutations in BRCAI and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol 2001; 19: 2247-2253.

Li FP, Fraumeni JF Jr: Sofl-tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-752.

Menkiszak J, et al.: Hereditary ovarian cancer: summary of 5 years of experience. Ginekol Pol 1998; 69: 283-287.

Loman N, et al.: Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancet 2000; 36: 1365-1373.

Lubiński J, et al.: BRG47-positive breast cancers in young women from Poland. Breast Cancer Res Treal 2006; 99; 71-76.

Lakhani SR: The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res 1999; 1; 31-35.

Górski B, et al.: Founder mutations in the BRCAI gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66: 1963-1968.

Loman N, et al.: Steroid receptors in hereditary breast carcinomas associated with BRCAI or BRCA2 mutations or unknown susceptibility genes. Cancer 1998; 83: 310-319.

Wooster R, et al.: Locaiisation of a breast cancer susceptibility gene BRCA2, to chromosome I3ql2-13 Science 1994; 265: 2088-2090.

Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCAI and BRCA2 in a populatior based series of breast cancer cases. Br J Cancer 2000; 83: 1301-1308.

Ford D, et al.: Genetic heterogeneity and penetrance analysis of the BRCAI and BRCA2 genes in breasi cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.

Hopper JL, et al.: Australian Breast Cancer Family Study. Population-based estimate ofthe average agr specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCAI anc BRCAJ2. Cancer Epidemiol Biomarkers Prev 1999; 8: 741-747.

6.

7.

j§C:^:v

i>

'k ź

TH o.

jf il.

12.

13.

If u.

W15.

'16.

jjwir'

Ii'?,

Mć-

*•18

•C;19.

po.

?!£>!;•

V -21.

^2.

ifec

#^;23.

».r.y.

«k

ł.25,

%>26.

^27.

•

mik

lę_;-